Fluidigm sees Q4 revenue approximately $21M, consensus $19.53M Instrument revenue is expected to be approximately $12M and consumables revenue is expected to be approximately $8.5M. Fluidigm’s instrument installed base increased to approximately 920 units at the end of Q4.
News For FLDM From The Last 14 Days
Check below for free stories on FLDM the last two weeks.
Fluidigm upgraded to Outperform from Market Perform at Leerink Leerink upgraded Fluidigm to Outperform citing reasonable consensus revenue estimates and strong demand for single cell gene expression analysis tools. The firm has a $52 price target for shares.
Piper Jaffray's medtech analysts hold an analyst/industry conference call The MedTech Analyst Team focuses on Piper Jaffray's covered universe from the perspective of Technical Analyst Johnson ahead of 1Q14 earnings results on an Analyst/Industry conference call to be held on April 11 at 10 am.